Oramed Pharmaceuticals, Inc logo

ORMP

Oramed Pharmaceuticals, Inc

$8.92

Earnings Summary

Revenue
$0.67Mn
Net Profits
$-10.43Mn
Net Profit Margins
-1565.32%

Highlights

Revenue:

Oramed Pharmaceuticals, Inc’s revenue jumped 0.15% since last year same period to $0.67Mn in the Q1 2022. On a quarterly growth basis, Oramed Pharmaceuticals, Inc has generated -1.19% fall in its revenue since last 3-months.

Net Profits:

Oramed Pharmaceuticals, Inc’s net profit fell -126.24% since last year same period to $-10.43Mn in the Q1 2022. On a quarterly growth basis, Oramed Pharmaceuticals, Inc has generated -32.13% fall in its net profits since last 3-months.

Net Profit Margins:

Oramed Pharmaceuticals, Inc’s net profit margin fell -125.9% since last year same period to -1565.32% in the Q1 2022. On a quarterly growth basis, Oramed Pharmaceuticals, Inc has generated -33.72% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Oramed Pharmaceuticals, Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.23
EPS Estimate Current Year
-0.23

Highlights

EPS Estimate Current Quarter:

Oramed Pharmaceuticals, Inc’s earning per share (EPS) estimates for the current quarter stand at -0.23 - a 0% jump from last quarter’s estimates.

EPS Estimate Current Year:

Oramed Pharmaceuticals, Inc’s earning per share (EPS) estimates for the current year stand at -0.23.

Key Ratios

Key ratios of the Oramed Pharmaceuticals, Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-0.27

Highlights

Earning Per Share (EPS):

Oramed Pharmaceuticals, Inc’s earning per share (EPS) fell -58.82% since last year same period to -0.27 in the Q2 2022. This indicates that the Oramed Pharmaceuticals, Inc has generated -58.82% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-06-01
-0.23
-0.27
-17.39%
2022-05-12
-0.23
-0.27
-17.39%

Company Information

Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsulefor the treatment of diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901.

Organisation
Oramed Pharmaceuticals, Inc
Headquarters
New York, New York, US
Employees
12
Industry
Health Technology
CEO
Nadav Kidron